GlassScriptPhysician profile
Deborah L Hewitt
NPI 1346412632
$10,686.36
in general payments reported to CMS, 2019-2025
65 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,156 · 2022: $2,825 · 2023: $3,407 · 2024: $2,006 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,528 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,528.10 |
| Education | $176.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,131.07 | 2021-2025 | |
| Amgen INC. | $1,029.32 | 2021-2023 | Kyprolis, Vectibix, Xgeva |
| Janssen Biotech, INC. | $708.78 | 2021-2024 | Imbruvica, Erleada, Darzalex |
| Celgene Corporation | $578.26 | 2022-2024 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $541.56 | 2021-2025 | Padcev, Xtandi, Xospata |
| Merck Sharp & Dohme LLC | $506.34 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $452.51 | 2021-2024 | Calquence, Lynparza, Enhertu |
| Lilly USA, LLC | $440.10 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $342.83 | 2021-2024 | Opdivo, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $338.65 | 2021-2024 | Ninlaro, Vpriv |
| Octapharma USA, INC. | $252.76 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Eisai INC. | $241.09 | 2021-2023 | |
| Daiichi Sankyo INC. | $238.03 | 2021-2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $227.67 | 2021-2024 | Libtayo |
| Exelixis INC. | $221.40 | 2021-2025 | Cabometyx |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.04 | 2021-2025 | |
| Genzyme Corporation | $172.59 | 2021-2024 | |
| Stemline Therapeutics INC. | $167.38 | 2023-2024 | Orserdu, Elzonris |
| Pfizer INC. | $164.17 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $153.82 | 2021-2024 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $128.85 | 2022-2024 | Tecentriq, Rozlytrek, Alecensa |
| Deciphera Pharmaceuticals INC. | $122.69 | 2021-2024 | Qinlock |
| Blueprint Medicines Corporation | $121.98 | 2023-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $120.61 | 2021-2023 | |
| Seagen INC. | $119.93 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Recordati_rare_diseases_inc. | $115.54 | 2023-2024 | Sylvant |
| Alexion Pharmaceuticals, INC. | $111.40 | 2021-2023 | Ultomiris |
| Emd Serono, INC. | $109.98 | 2021-2024 | |
| Pharmaessentia USA Corporation | $102.15 | 2023-2024 | Besremi |
| Coherus Oncology, INC. | $91.91 | 2023-2024 | |
| Glaxosmithkline, LLC. | $90.06 | 2021-2024 | Zejula, Jemperli, Shingrix |
| Myovant Sciences INC. | $88.39 | 2021-2022 | |
| Incyte Corporation | $79.40 | 2023-2024 | Monjuvi, Pemazyre, Jakafi |
| Jazz Pharmaceuticals INC. | $74.99 | 2022-2024 | Zepzelca |
| Sumitomo Pharma America, INC. | $73.13 | 2023-2024 | Orgovyx |
| Gilead Sciences, INC. | $72.03 | 2022-2023 | Trodelvy |
| Sobi, INC | $68.92 | 2022-2024 | |
| Array Biopharma INC | $67.43 | 2022-2024 | Mektovi, Lorbrena, Xalkori |
| Beigene USA, INC. | $63.48 | 2021-2024 | Brukinsa |
| Heron Therapeutics, INC. | $59.90 | 2022 | |
| Rigel Pharmaceuticals, INC. | $52.70 | 2022-2023 | Tavalisse, Rezlidhia |
| Tersera Therapeutics LLC | $50.13 | 2022-2023 | Quzyttir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.23 | 2021-2023 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $43.17 | 2021-2023 | Fotivda |
| Mirati Therapeutics, INC. | $42.62 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $41.38 | 2021-2024 | Xpovio |
| Pharmacosmos Therapeutics INC. | $37.66 | 2022-2024 | Monoferric |
| Spectrum Pharmaceuticals INC. | $36.04 | 2023-2024 | Rolvedon |
| Bayer Healthcare Pharmaceuticals INC. | $35.39 | 2023-2024 | |
| Foundation Medicine, INC. | $29.88 | 2021 | |
| Janssen Scientific Affairs, LLC | $29.73 | 2023 | Tecvayli |
| Fennec Pharmaceuticals, INC. | $26.06 | 2023-2024 | Pedmark |
| Alnylam Pharmaceuticals INC. | $23.33 | 2021 | |
| Axsome Therapeutics, INC. | $22.75 | 2025 | Symbravo |
| Immunogen, INC. | $18.51 | 2023 | Elahere |
| Pharmacyclics LLC, An Abbvie Company | $17.68 | 2023 | Imbruvica |
| Amneal Pharmaceuticals LLC | $17.11 | 2025 | Alymsys |
| Progenics Pharmaceuticals, INC. | $16.56 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.52 | 2025 | Rexulti |
| Taiho Oncology, INC. | $15.14 | 2021 | |
| Verity Pharmaceuticals INC. | $14.90 | 2023 | Trelstar |
| Acceleron Pharma, INC. | $14.69 | 2021 | |
| Acrotech Biopharma INC. | $14.28 | 2024 | Beleodaq |
| Kyowa Kirin, INC. | $13.69 | 2022 | |
| Eusa Pharma (US) LLC | $12.07 | 2022 |
Drugs and devices associated with these payments
Reblozyl $290Keytruda $290Cabometyx $209Kisqali $209Orserdu $153Imbruvica $152Jaypirca $150Libtayo $144Octagam Immune Globulin (Human) $142Opdivo $142Lynparza $137Xtandi $133Verzenio $124Orgovyx $123Ayvakit $122Sylvant $116Padcev $114Retevmo $108Calquence $108Venclexta $103Besremi $102Elitek $98.00Pluvicto $95.01Pomalyst $94.29Comirnaty $94.22Erleada $93.66Udenyca $91.91Tecentriq $91.05Tecvayli $90.40Darzalex $88.60Sarclisa $86.80Enhertu $86.77Ultomiris $82.66Paxlovid $77.33Carvykti $76.30Mekinist $75.54Ninlaro $74.16Qinlock $65.30Promacta $60.14Scemblix $59.65Elahere $58.53Kyprolis $57.98Zepzelca $56.72Nplate $53.39Xgeva $53.39Vectibix $53.39Bosulif $51.90Pemazyre $51.31Monjuvi $51.31Piqray $47.07Onivyde $45.70Somatuline Depot $45.70Jakafi $43.09Krazati $42.62Xospata $42.14Rezlidhia $38.89Tavalisse $38.89Rybrevant $37.66Lutathera $37.14Tafinlar $36.87Rolvedon $36.04Nubeqa $35.39Xofigo $35.39Doptelet $35.05Lumakras $34.40Mektovi $34.02Xalkori $34.02Lorbrena $34.02Braftovi $34.02Trodelvy $32.21Talvey $31.44Xpovio $30.30Tukysa $27.41Pedmark $26.06Quzyttir $25.89Elrexfio $24.65Monoferric $23.74Panzyga $23.03Symbravo $22.75Epkinly $22.17Rozlytrek $22.13Alecensa $22.13Vpriv $21.90Tasigna $19.94Jemperli $19.04Zejula $19.04Gilotrif $18.70Lenvima $18.61Alymsys $17.11Welireg $16.92Rexulti $16.52Adcetris $16.48Akeega $15.54Balversa $15.54Polivy $15.49Lunsumio $15.49Fotivda $15.47Fabhalta $15.33Trelstar $14.90Elzonris $14.58
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Hewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.